Douglas Klaiber is an accomplished executive with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as the Chief Executive Officer of Q-VANT Biosciences since January 2022, Klaiber leads efforts to address supply chain challenges for QS-21 and Quillaja-based saponin adjuvants, utilizing next-generation technology to significantly increase production capabilities. Since April 2019, Klaiber has also held the CEO position at Urobiome Therapeutics, focusing on the development of innovative therapies for urinary microbiome-related diseases. Prior roles include CEO at Naturex-DBS LLC and Decas Botanical Synergies, as well as Sr. Director of Marketing at Taqua Systems. Klaiber holds a B.S. in Mechanical Engineering from Penn State University and an MBA from the University of Pennsylvania (Wharton).
This person is not in any teams
Q-VANT Biosciences
Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivalled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com.